Guttman-Yassky, E. ., Weidinger, S. ., Simpson, E. ., Gooderham, M. ., Irvine, A. ., Spelman, L. ., Silverberg, J. ., Elmaraghy, H. ., DeLuca-Carter, L. ., Buziqui Piruzeli, M. L. ., Hu, C. ., Yang, F. E. ., Pierce, E. ., Bardolet, L. ., & Thaci, D. . (2023). Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine, 7(6), s271. https://doi.org/10.25251/skin.7.supp.271